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Clinics 
Age and sex 
66 years old male patient. 
Previous history 
No preleukemia. No previous malignancy. No 
inborn condition of note. 
Organomegaly 
Hepatomegaly (enlarged liver (+ 20 cm)), 
splenomegaly, no enlarged lymph nodes , no central 
nervous system involvement. 
Blood 
WBC : 46 X 10
9
/l 
HB : 8.5 g/dl 
Platelets : 239 X 10
9
/l 
Blasts : 15% 





Rearranged Ig Tcr: NA 
Pathology: NA 
Electron microscopy: NA 
 
Diagnosis 
Polycythemia vera. Myelofibrosis: hypocellular 
bone marrow with marked increase in reticulin 
fibres. AML M2. 
Survival 
Date of diagnosis: 01-1980 
Treatment 
Bleeding therapy and acethylsalicylic acid. 2005 -
2008: Etanercept (anti-TNF alpha). 2007: 
Hydroxyurea. Sept. 2008: Splenectomy. Feb. 2008: 
Pomalidomide, suspended after 1 month because of 
a severe neutropeny. Feb 2009: Bone Marrow 
allograft. 
Complete remission : no  (March-November 2009: 
complete hematological remission; molecular 
remission not reached (JAK-2 positivity in June 
2009)) 
Treatment related death : no   
Relapse : no   
Status: Death. Last follow up: 11-2010 (due to 
gastrointestinal hemorrhage). 
Survival: nearly 30 years. 
Karyotype 
Sample: Bone marrow biopsy in Dec. 2008 
Culture time: 24 and 48 h. 
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Banding: Cytogenetic analysis performed in QFQ 
banding; band level: 400. 
Results 




Probes: whole-chromosome painting probes (wcp) and 
centromeric (CEP) probes of chromosomes 9 (9p11-q11 





Polycythemia Vera (PV) is a clonal 
myeloproliferative disorder characterized by 
excessive erythrocyte production, which may 
evolve into myelofibrosis and acute myeloid 
leukemia. Transformation to myelofibrosis occurs 
in 15-20% of cases and leukemic transformation in 
5-10% of patients. The median survival time is 8-11 
years and the median age at diagnosis is over 60 
years. Normal karyotype is present at diagnosis in 
the majority of patients, while during 
transformation several acquired chromosome 
anomalies are present as trisomy 9 and gains in 9p. 
The activating JAK2 V617F mutation, present in 
the majority of patients with PV, seems to have a 
primary role in the pathogenesis of 
myeloproliferative neoplasms. The JAK2 gene 
maps to 9p24, so patients carrying gains of 9p have 
an extra copy of the gene, in its normal or mutated 
form, leading to a gain of function. 
The rearrangement here reported, 
der(9;18)(p10;q10), is rarely detected in patients 
with PV, myelofibrosis, essential thrombocythemia 
and therapy-related AML. Some authors suggest 
that the simultaneous presence of both JAK2 
V617F mutation and this rearrangement could 
define a subgroup of PV patients with the 
proliferative phenotype of the disease, at high risk 
of transformation into postpolycythemic 
myelofibrosis and potentially acute myeloid 
leukemia. 
We describe a new case of der(9;18)(p10;q10) 
detected in a patient with AML evolved from post-
polycythemic myelofibrosis. The patient was 
diagnosed with PV in 1980 and died in 2010. He 
was in good health for several years after diagnosis 
with bleeding treatment and low dose aspirin, then 
he showed a progressive worsening of anemia with 
liver enlargement and splenomegaly. In February 
2008 the diagnosis was of myelofibrosis post PV in 
progression. In December 2008, when the leukemic 
transformation was evident, the cytogenetic 
analysis on bone marrow aspirate found the 
unbalanced translocation leading to 
der(9;18)(p10;q10), with trisomy of the short arms 
of chromosome 9 and monosomy of the short arms 
of chromosome 18. FISH experiments with specific 
alphoid centromeric probes for chromosome 9 and 
18 showed both positive signals on the der(9). 
Subsequent molecular analysis detected the 
presence of the JAK2 V617F mutation.  
The patient here reported had a classical evolution 
of the disease, after a very long polycythemic phase 
with a noteworthy survival time likely correlated to 
the young age of the patient when PV occurred. 
Because of the absence of cytogenetic results at 
diagnosis and during the polycythemic phase, we 
cannot fully evaluate the significance of 
der(9;18)(p10;q10) in the natural history of the 
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disease before its evolution. Future reports could 
make clear this not negligible aspect. 
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